ArticleCell death discovery2026
The omega-3 DHA induces pyroptosis and mitochondrial dysfunction in ovarian cancer cells via ROS and caspase-1 activation.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2026Review
- The Impact of Oxidative Stress Imbalance on Ovarian Function and Its Mechanisms.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Ovarian cancer remains one of the most lethal gynecologic malignancies due to late diagnosis, limited treatment options, and frequent chemoresistance. Docosahexaenoic acid (DHA), a long-chain omega-3 polyunsaturated fatty acid, has been associated with anti-tumor effects in various cancer models. Here, we investigated the effects of DHA on cell death, oxidative stress, and mitochondrial function in A2780 human ovarian cancer cells. Our data show that DHA decreases cell viability and proliferation in a dose- and time-dependent manner, promoting lytic cell death with increased membrane permeability and LDH release. We identified pyroptosis as the predominant death mechanism, evidenced by caspase-1 activation, pore formation, and mitochondrial dysfunction. DHA treatment rapidly increased intracellular reactive oxygen species (ROS) and mitochondrial superoxide levels, which were essential for both membrane pore formation and the loss of mitochondrial membrane potential. Notably, ROS scavenging with N-acetylcysteine reversed DHA-induced mitochondrial damage and pyroptosis, indicating ROS dependence. Furthermore, DHA reduced mitochondrial content and impaired spare respiratory capacity, suggesting disrupted mitochondrial adaptability. Caspase-1 inhibition restored both mitochondrial integrity and respiratory function, highlighting a mechanistic role for caspase-1 in mediating DHA-induced bioenergetic dysfunction. Collectively, our findings reveal that DHA compromises ovarian cancer cell survival by triggering ROS- and caspase-1-dependent pyroptosis and mitochondrial dysfunction. This study expands the understanding of DHA's anti-cancer mechanisms and positions it as a promising candidate for adjuvant therapies targeting mitochondrial vulnerabilities and immunogenic cell death pathways in ovarian cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.